Elekta aligns with European medtech peers, shares track sector performance

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 09:04.

Elekta (SE0000163628) starts the week with a stable analyst consensus that positions the Stockholm-listed company alongside European medtech names such as Siemens Healthineers and Philips. Market data from Stockholm and sector comparisons set the reference points for the shares according to recent analyst compilations.

Analyst view on Elekta today

Consensus data compiled by MarketScreener show that a majority of analysts rate Elekta between Hold and Buy, with an average target price in the mid-double-digit Swedish krona range, underlining a cautious but constructive stance on the stock MarketScreener consensus overview. The company is widely followed given its position in radiation therapy equipment, which places it in direct comparison with U.S. peer Varian, now part of Siemens Healthineers.

Analysts factor in Elekta's recurring revenue from software and service contracts, which historically has provided a stabilizing element to cash flows and earnings. Several houses highlight that capital equipment cycles in oncology centers and hospitals remain a key driver for new orders and long-term installed base growth.

How Elekta compares with medtech peers

Compared with Siemens Healthineers and Philips in the broader imaging and therapy space, Elekta is more narrowly focused on radiation oncology, which can lead to higher earnings volatility but also a clearer strategic profile according to sector research notes recent Reuters sector commentary. The company competes globally with systems used in comprehensive cancer centers, where procurement decisions are often long-dated and tied to public budgets.

International investors often benchmark Elekta against U.S.-listed medtech constituents of the S&P 500, focusing on growth in installed base and service revenue. The shares trade on Nasdaq Stockholm in Swedish krona, and valuation multiples are frequently compared with European healthcare names in the Stoxx Europe 600.

The product behind Elekta's revenue

Elekta generates a large share of its revenue with its linear accelerator platform Elekta Infinity, which is used in radiation therapy for cancer treatment. The systems combine hardware and software to deliver high-precision doses while integrating imaging and treatment planning workflows in oncology departments.

Where the Elekta shares trade

The Elekta shares (SE0000163628) trade on Nasdaq Stockholm at 72.50 Swedish krona as of 2026-06-26, 09:00.

This article is for informational purposes only and does not constitute investment advice, an offer or solicitation to buy or sell any securities. Investors should conduct their own research or consult a professional advisor before making investment decisions.